Mar 22, 2024
News & Events
Press Releases
Feb 22, 2024
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Jan 16, 2024
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Jan 3, 2024
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Events
11th Annual Tumor Models Conference
EHA 2023 Hybrid Congress
BIO International Convention
AACR ANNUAL MEETING 2023
In the News
Precision Medicine Online